Lifecore Biomedical (NASDAQ:LFCR) Rating Increased to Hold at Wall Street Zen

Key Points

• Lifecore Biomedical's stock rating was upgraded from "sell" to "hold" by analysts at Wall Street Zen.
• Despite recent upgrades, Lifecore Biomedical reported a loss of ($0.10) earnings per share, missing the consensus estimate of ($0.09).
• Major shareholder Aron R. English sold over 1.1 million shares of the company, decreasing their ownership by 73.32%.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Separately, William Blair started coverage on shares of Lifecore Biomedical in a report on Wednesday, May 21st. They issued an "outperform" rating on the stock. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.00.

Lifecore Biomedical Trading Down 0.1%

LFCR traded down $0.01 on Friday, hitting $7.24. The company had a trading volume of 67,699 shares, compared to its average volume of 117,821. The firm has a market cap of $270.85 million, a P/E ratio of -5.53 and a beta of 0.65. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $8.85. The company's fifty day moving average price is $7.56 and its 200 day moving average price is $6.78. The company has a current ratio of 2.84, a quick ratio of 1.77 and a debt-to-equity ratio of 113.76.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $36.44 million during the quarter, compared to analysts' expectations of $35.36 million. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. Lifecore Biomedical has set its FY 2026 guidance at EPS. As a group, equities analysts expect that Lifecore Biomedical will post -0.91 earnings per share for the current year.

Insider Transactions at Lifecore Biomedical

In other Lifecore Biomedical news, major shareholder Aron R. English sold 150,419 shares of the business's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $7.12, for a total transaction of $1,070,983.28. Following the sale, the insider directly owned 264,180 shares in the company, valued at $1,880,961.60. This represents a 36.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 1,386,060 shares of company stock worth $9,126,684 in the last 90 days. 32.20% of the stock is owned by corporate insiders.

Institutional Trading of Lifecore Biomedical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Lifecore Biomedical by 14.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock worth $104,000 after buying an additional 1,886 shares during the period. Bridgeway Capital Management LLC increased its stake in shares of Lifecore Biomedical by 2.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 78,800 shares of the company's stock worth $585,000 after buying an additional 1,900 shares during the period. Steward Partners Investment Advisory LLC increased its stake in shares of Lifecore Biomedical by 8.4% during the second quarter. Steward Partners Investment Advisory LLC now owns 32,761 shares of the company's stock worth $266,000 after buying an additional 2,528 shares during the period. Wells Fargo & Company MN increased its stake in shares of Lifecore Biomedical by 29.0% during the fourth quarter. Wells Fargo & Company MN now owns 13,381 shares of the company's stock worth $99,000 after buying an additional 3,012 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Lifecore Biomedical by 3.8% during the first quarter. Bank of New York Mellon Corp now owns 83,663 shares of the company's stock worth $589,000 after buying an additional 3,091 shares during the period. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.